In MS patients, differences observed in factors which mediate vitamin D function such as higher plasma DBP level compared to healthy individuals [1] and VDR polymorphism [23] add more complexity to the question about vitamin D supplementation. This evidence concerns the gene VDR and myeloid sarcoma.